Skip to main content

Market Overview

UPDATE: Piper Jaffray Upgrades AtriCure to Overweight on New Management Confidence

Share:

Piper Jaffray raised its rating on AtriCure (NASDAQ: ATRC) from Neutral to Overweight and increased its price target from $6 to $10.

Piper Jaffray said, "We are upgrading ATRC shares to Overweight from Neutral (and raising our PT to $10 from $6) after meeting with the newly appointed CEO, Michael Carrel. With the CEO slot filled, we believe a level of normalcy should return to operations, allowing us to return to our original thesis. As a reminder, before the former CEO exited unexpectedly, our positive viewpoint had centered on recent FDA approval that finally put Synergy “on-label” for its intended use. While the product has been for sale in the US for the last 11 years, the potential revenue was severely constrained without the ability to market, train, hold symposia, or in any way promote the use of the ablation technology for the treatment of AF."

AtriCure closed at $6.43 on Thursday.

Latest Ratings for ATRC

DateFirmActionFromTo
Feb 2021SVB LeerinkMaintainsOutperform
Feb 2021NeedhamMaintainsBuy
Dec 2020SVB LeerinkMaintainsOutperform

View More Analyst Ratings for ATRC
View the Latest Analyst Ratings

 

Related Articles (ATRC)

View Comments and Join the Discussion!

Posted-In: Piper JaffrayAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

Latest Ratings

StockFirmActionPT
NIUDaiwa CapitalInitiates Coverage On41.5
QMCONorthland Capital MarketsInitiates Coverage On12.0
IBKRJefferiesInitiates Coverage On89.0
MRETFTD SecuritiesDowngrades18.5
SWKSGoldman SachsDowngrades135.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com